Daily Brief Thematic (Sector/Industry): Our Three Worst Calls in 2022: Signs of Reversal in 2023 and more

• Xinjiang Goldwind Science & Technology (2208 HK) performed badly in 2022 and with sustained pressure on WTG price, earnings will stay under pressure. We will only pick up post-FY22 result.
• Removal of “zero COVID” policy and consumption recovery should revive sportswear business of China Dongxiang Group (3818 HK). Improvement in equity market will boost its investment portfolio value.   
• Valuation retreat for China Longyuan Power (916 HK) has made it more attractive. Rebound in electricity demand, continued green energy push and potential asset injection are drivers. 

What does 2023 have in store for the Chinese healthcare industry? In the next webinar, we speak with Insight Provider Xinyao (Criss) Wang on just that, as she shares with us the landscape of the Chinese healthcare industry in 2023. From its outlook in 2023, to the opportunities present, Criss will share with us her thoughts and insights in this next episode of our Webinar Wednesdays. Have any burning questions about the Chinese healthcare industry for 2023? Get them answered in the live Q&A that will conclude the session. 

The webinar will be hosted on Wednesday, 11 January 2023, 17:00 SGT/HKT.

A Hong Kong/China Healthcare Analyst, Criss has over 13 years’ worth of experience in both finance and healthcare. She covers clinic operations, investment and equity research in both the Chinese and overseas markets.

• We again write about one stock each from the large, mid and small cap portfolios, briefly giving the reasons for their inclusion.
• The three companies we write about this week are Abbvie Inc (ABBV US), Becton Dickinson and Co (BDX US) and Ciena Corp (CIEN US) 
• For the seven weeks since inception ended 6 Jan the combined innovation portfolio was +1.6%, versus DJIA -0.3%, S&P500 -1.8%, Nasdaq -5.2% & MSCI-ACWI-ETF +0.1%, all in US$ terms